Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:60 - Any
Updated:3/13/2019
Start Date:July 17, 2018
End Date:January 2022
Contact:Jason Do
Email:Jdo@acadia-pharm.com
Phone:858-261-2971

Use our guide to learn which trials are right for you!

A 52-Week Open-label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

The purpose of this study is to evaluate the long-term safety and tolerability of
pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to
neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.


Inclusion Criteria:

1. Subject satisfied all entry criteria for the antecedent pimavanserin study

2. Subject completed the antecedent study; or was participating in a pimavanserin study
that the Sponsor ended early

3. Has a designated study partner/caregiver who meets the following requirements:

1. In the Investigator's opinion, is in contact with the subject frequently enough
to accurately report on the subject's symptoms and whether or not the subject is
taking the study drug

2. In the Investigator's opinion, is considered reliable in providing support to the
subject to help ensure compliance with study treatment, study visits, and
protocol procedures

3. Is fluent in the local language in which study assessments will be administered

4. Agrees to participate in study assessments, has the capacity to provide informed
consent, and provides written consent to participate in the study

4. Subject is willing and able to provide informed consent.

5. If the subject is female, she must not be pregnant or breastfeeding. She must also be
of non-childbearing potential (defined as either surgically sterilized or at least 1
year postmenopausal) or must agree to use a clinically acceptable method of
contraception or be abstinent during the study and 1 month following completion of the
study.

Exclusion Criteria:

1. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for
the study, due to AEs, medical condition, or noncompliance with investigational
product or study procedures in the antecedent study, or is judged to be a danger to
self or others

2. Is in hospice, is receiving end-of-life palliative care, or has become bedridden

3. Has any of the following ECG results at the EOT/ET visit of the antecedent study:

a. If the subject is not on citalopram, escitalopram, or venlafaxine:

i. QTcF >450 ms, if QRS duration <120 ms

ii. QTcF >470 ms, if QRS duration ≥120 ms

b. If the subject is on citalopram, escitalopram, or venlafaxine:

i. QTcF >425 ms, if QRS duration <120 ms

ii. QTcF >450 ms, if QRS duration ≥120 ms

4. Has a heart rate <50 beats per minute. If bradycardia is secondary to iatrogenic or
treatable causes and these causes are treated, a heart rate assessment can be repeated
at the EOT/ET visit of the antecedent study.

5. Has clinically significant laboratory abnormalities in the antecedent study that, in
the judgment of the Investigator or Medical Monitor, would either:

1. jeopardize the safe participation of the subject in the study; OR

2. would interfere with the conduct or interpretation of safety or efficacy
evaluations in the study

6. Is suicidal at Visit 1 (Baseline)

7. Has developed a medical condition that in the judgment of the Investigator, would
increase the risk associated with taking study medication or significantly interfere
with the conduct or interpretation of the study

8. Requires treatment with a medication or other substance that is prohibited by the
protocol

9. Has a significant sensitivity or allergic reaction to pimavanserin or its excipients

10. Is an employee of ACADIA, or has a family member who is an employee of ACADIA

Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to
ensure that all criteria for study participation are met. Patients may be excluded from the
study based on these assessments (and specifically, if it is determined that their baseline
health and psychiatric condition do not meet all pre-specified entry criteria).
We found this trial at
13
sites
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Bourgas,
Click here to add this to my saved trials
Hialeah, Florida 33012
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Media, Pennsylvania 19063
?
mi
from
Media, PA
Click here to add this to my saved trials
Miami, Florida 33125
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mount Arlington, New Jersey 07856
?
mi
from
Mount Arlington, NJ
Click here to add this to my saved trials
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Newton, Massachusetts 02459
?
mi
from
Newton, MA
Click here to add this to my saved trials
North Palm Beach, Florida 33408
?
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Santa Ana, California 92705
?
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Shaker Heights, Ohio 44122
?
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
3201 Wedgewood Lane
The Villages, Florida 32162
?
mi
from
The Villages, FL
Click here to add this to my saved trials